N-ethyl-N-[[(2S)-piperidin-2-yl]methyl]ethanamine | 120990-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-ethyl-N-[[(2S)-piperidin-2-yl]methyl]ethanamine
• CAS: 120990-93-4
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: WTIYGHQFUHZRDA-JTQLQIEISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N-ethyl-N-[[(2S)-piperidin-2-yl]methyl]ethanamine 、 2-(5-oxo-7,8-dihydro-6H-naphthalen-2-yl)acetyl chloride 在 potassium carbonate 作用下， 以 二氯甲烷 为溶剂， 反应 8.0h， 生成 6-[2-((S)-2-Diethylaminomethyl-piperidin-1-yl)-2-oxo-ethyl]-3,4-dihydro-2H-naphthalen-1-one
  参考文献：
  名称：

  Selective .kappa.-Opioid Agonists: Synthesis and Structure-Activity Relationships of Piperidines Incorporating an Oxo-Containing Acyl Group

  摘要：

  This study describes the synthesis and the structure-activity relationships (SARs) of the (S)-(-)-enantiomers of a novel class of 2-(aminomethyl)piperidine derivatives, using K-opioid binding affinity and antinociceptive potency as the indices of biological activity. Compounds incorporating the 1-tetralon-6-ylacetyl residue (30 and 34-45) demonstrated an in vivo antinociceptive activity greater than predicted on the basis of their kappa-binding affinities. In particular, (2S)-2-[(dimethylamino)methyl]-1-[(5,6,7,8-tetrahydro-5-oxo-2-naphthyl)acetyl]piperidine (34) was found to have a potency similar to spiradoline in animal models of antinociception after subcutaneous administration, with ED(50)s of 0.47 and 0.73 mu mol/kg in the mouse and in the rat abdominal constriction tests, respectively. Further in vivo studies in mice and/or rats revealed that compound 34, compared to other selective K-agonists, has a reduced propensity to cause a number of K-related side effects, including locomotor impairment/sedation and diuresis, at antinociceptive doses. For example, it has an ED(50) Of 26.5 mu mol/kg sc in the rat rotarod model, exhibiting a ratio of locomotor impairment/sedation vs analgesia of 36. Possible reasons for this differential activity and its clinical consequence are discussed.

  DOI：

  10.1021/jm00047a006
• 作为产物：
  描述：

  (S)-N,N-diethylpiperidine-2-carboxamide 在 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.0h， 生成 N-ethyl-N-[[(2S)-piperidin-2-yl]methyl]ethanamine
  参考文献：
  名称：

  （2S）-1-（芳基乙酰基）-2-（氨基甲基）哌啶衍生物：新颖的高选择性κ阿片类镇痛药。

  摘要：

  本文描述了新型的1-（芳基乙酰基）-2-（氨基甲基）哌啶衍生物的合成和构效关系，作为κ阿片类镇痛药。通过计算研究和1H NMR定义了具有60度扭转角（N1C2C7N8）的药效团的活性构象。芳香族部分取代的定量结构-活性关系研究表明，对位和/或间位存在吸电子和亲脂性取代基是良好的镇痛活性和κ亲和力所必需的。铅化合物（2S）-1-[（（3,4-二氯苯基）乙酰基] -2-（吡咯烷-1-基甲基）哌啶盐酸盐和（2S）-1- [4-（三氟甲基）苯基]乙酰基] -2 -（吡咯烷-1-基甲基）哌啶盐酸盐的Kappa / mu选择性最高（分别为6500：1和4100：1）以及迄今为止鉴定出的最有力的（κκ0.24和0.57 nM）κ配体。在抗伤害感受的小鼠甩尾模型中，化合物14（ED50 = 0.05 mg / kg sc）的效力是吗啡的25倍，效力是标准Kappa配体U-50488的16倍。

  DOI：

  10.1021/jm00105a061

文献信息

• Orthogonal Catalysis for an Enantioselective Domino Inverse‐Electron Demand Diels−Alder/Substitution Reaction
  作者：Sebastian Beeck、Sebastian Ahles、Hermann A. Wegner

  DOI：10.1002/chem.202104085

  日期：2022.1.24

  have been accessed through a novel enantioselective domino process. Lewis acid activation and organocatalysis were combined to generate the products from readily available substances. A new chiral amine catalyst ensures high enantiomeric ratios. Both enantiomers of the product can be derived and the configuration on the newly generated stereo centers were unambiguously related to the chirality of the

  硫醚取代的反式-1,2-二氢萘已通过一种新颖的对映选择性多米诺骨牌工艺获得。将路易斯酸活化和有机催化相结合，从容易获得的物质中生成产物。新型手性胺催化剂可确保高对映体比率。可以衍生出产物的两种对映异构体，并且新生成的立体中心的构型与胺的手性明确相关。
• NOVEL 1-(2H-1-OXO-3,4-DIHYDRONAPHTYL-6)-ACETYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE
  申请人：Dr. Lo. Zambeletti S.p.A.

  公开号：EP0594611A1

  公开（公告）日：1994-05-04
• US5428042A
  申请人：——

  公开号：US5428042A

  公开（公告）日：1995-06-27
• [EN] NOVEL 1-(2H-1-OXO-3,4-DIHYDRONAPHTYL-6)-ACETYL-PIPERIDINES, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USE
  申请人：DR. LO. ZAMBELETTI S.P.A.

  公开号：WO1991017116A1

  公开（公告）日：1991-11-14

  (EN) Novel azacyclic derivatives of formula (I), in which R1 and R2 are each linear or branched alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, cycloalkenyl or alkynyl; R3 and R4 are identical, and each is a hydrogen or alkyl; and R5 is hydrogen or alkyl. Process for their preparation and their use in medicine.(FR) Nouveaux dérivés azacycliques de formule (I), dans laquelle: R1 et R2 représentent chacun un alkyle, cycloalkyle, cycloalkylalkyle, alcényle, cycloalcényle ou alcynyle linéaires ou ramifiées; R3 et R4 sont identiques et chacun représente un hydrogène ou alkyle; et R5 est hydrogène ou alkyle. Procédé de préparation et utilisation en médecine.